TABLE 2.
Result of susceptibility testing
| Agent | MIC (μg/ml) |
|
|---|---|---|
| E. coli DH5α(pBC-TLA-3b) | E. coli DH5α(pBC-SK+) | |
| Ampicillin | 128 | 2 |
| Cephalothin | 128 | 8 |
| Cefuroxime | 256 | 8 |
| Ceftazidime | 64 | 0.25 |
| Ceftazidime plus: | ||
| Avibactama | 0.25 | 0.25 |
| OP0595a | ≤0.13 | ≤0.13 |
| Clavulanic acida | 0.5 | 0.25 |
| Tazobactama | 1 | 0.25 |
| Sulbactama | 4 | 0.25 |
| Cefotaxime | 16 | ≤0.13 |
| Cefotaxime plus: | ||
| Avibactama | ≤0.13 | ≤0.13 |
| OP0595a | ≤0.13 | ≤0.13 |
| Clavulanic acida | ≤0.13 | ≤0.13 |
| Tazobactama | ≤0.13 | ≤0.13 |
| Sulbactama | 1 | ≤0.13 |
| Cefepime | 0.25 | ≤0.13 |
| Cefoxitin | 4 | 4 |
| Aztreonam | 8 | ≤0.13 |
| Imipenem | 0.25 | 0.25 |
| Meropenem | ≤0.13 | ≤0.13 |
| Avibactam | 32 | 32 |
| OP0595 | 4 | 4 |
a
The concentration was fixed at 4 μg/ml.
b
The pBC-TLA-3 vector was constructed in a previous study (8).